It also permits within model parallel action so the analysis work for one model can be divided between several CPUs. It supports between model parallelizing, allowing two models to be run together on different processors. Phoenix NLME 8.0 takes advantage of grid computing in several ways. It has been only 12 months since the last Phoenix release, and we have added several important new features to the software to allow key drug development decisions to be made quicker,вЂќ said David Munro, President of Phoenix Technologies at Certara. вЂњPhoenix is considered the gold standard in PK/PD modeling and simulation, and we take our responsibility to deliver continuous improvement and innovation very seriously. This enables safe and effective new therapeutics to advance more efficiently through the different stages of clinical trials,вЂќ said US FDA Commissioner Scott Gottlieb, M.D. вЂњModeling and simulation play a critical role in organizing diverse data sets and exploring alternate study designs. Phoenix is also employed by many global regulatory agencies for submittal review, including 11 divisions of the FDA.

Phoenix is used by 6,000 researchers at 1,500 biopharmaceutical companies and academic institutions in 60 countries. Included in this Phoenix rollout are Phoenix WinNonlin 8.0, Phoenix NLME 8.0, Phoenix Validation Suite 8.0 and Phoenix in vitro-in vivo correlation (IVIVC) Toolkit 8.0. Phoenix is the most advanced, intuitive, and widely-used software for pharmacokinetic (PK), pharmacodynamic (PD) and toxicokinetic (TK) modeling and simulation. Certara, a global provider of model-informed drug development and regulatory science, announced the launch of Phoenix 8.0.

Phoenix software winnonlin